Protalix Biotherapeutics, Inc. annual report, Q4 FY2005

Business Context and Reporting Period

Company: Orthodontix, Inc. (Note: Input metadata referenced Protalix Biotherapeutics, but the filing text is for Orthodontix, Inc.)
Filing Type: Form 10-KSB (Annual Report)
Period: Fiscal Year Ended December 31, 2005
Status: Shell Company / Pre-Acquisition Vehicle

Orthodontix, Inc. ceased its original orthodontic practice management operations in 1999 and terminated all practice affiliations by 2001. As of the reporting period, the Company operates as a shell company with no active business operations, devoting management time exclusively to identifying potential merger or acquisition candidates in industries such as health care, manufacturing, and banking.

Key Financial Metrics

Metric 2005 2004
Revenue $0 $0
Net Loss $(74,931) $(160,070)
Loss Per Share (Basic/Diluted) $(0.02) $(0.05)
General & Administrative Expenses $93,295 $165,582
Interest Income $14,150 $5,512
Cash and Cash Equivalents (Year End) $985,238 $563,713
Total Liabilities $72,930 Filing text does not provide a clear total for 2004
Stockholders' Equity $914,431 $495,362

Material Changes vs. Prior Period

  • Reduced Operating Loss: Net loss decreased by approximately 53% from $160,070 in 2004 to $74,931 in 2005, primarily due to a significant reduction in General and Administrative expenses (down from $165,582 to $93,295).
  • Capital Raise: In November 2005, the Company sold 2,915,428 shares of common stock to an existing shareholder for $494,000. This transaction resulted in a change of majority control to a previously unrelated third party.
  • Increased Liquidity: Cash and cash equivalents increased by $421,525 to $985,238, driven by the proceeds from the stock issuance and higher interest income ($14,150 vs. $5,512).
  • Stock Price Volatility: While trading between $0.11 and $0.21 for most of 2005, the stock price spiked to a high of $5.50 in the fourth quarter, coinciding with the capital raise.

Outlook, Risks, and Management Commentary

  • Plan of Operation: Management intends to effect a merger, acquisition, or business combination using a combination of common stock, cash on hand, or other funding sources. No assurances are given that a transaction will occur.
  • Liquidity: Management believes current operating funds ($985,238) are sufficient to cover expenses for at least the next twelve months. The Company has no ongoing contractual commitments.
  • Risks: The Company is a shell company with no revenue. Success depends entirely on consummating a business combination. There is a risk that funding sources may not be available or that a transaction cannot be completed on favorable terms.
  • Accountant Changes: The Company changed auditors twice in recent years. PricewaterhouseCoopers resigned in 2004; Salberg & Co. was engaged in 2005 but dismissed in September 2005; Sherb and Company, LLP was engaged to audit the 2005 statements. No disagreements were reported regarding accounting principles.

Investor Verification Checklist

  • Shell Status: Verify the Company's status as a shell company with no operating revenue and its reliance on a future merger for viability.
  • Change of Control: Confirm the details of the November 2005 stock sale that transferred majority control to a new third-party shareholder.
  • Cash Runway: Assess the sustainability of the $985,000 cash balance against the historical burn rate of ~$75,000 annually.
  • Related Party Transactions: Review the compensation of the CFO (paid via an accounting firm where he is a shareholder) and the rent-free office space provided by Transworld Investment Corporation (TIC), where the CEO and a Director are officers.
  • Accumulated Deficit: Note the significant accumulated deficit of approximately $3.8 million as of December 31, 2005.